دورية أكاديمية

Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer.

التفاصيل البيبلوغرافية
العنوان: Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer.
المؤلفون: Evans JP; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Winiarski BK; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Sutton PA; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Jones RP; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Ressel L; Department of Veterinary Pathology, Institute of Veterinary Science, University of Liverpool, Liverpool, United Kingdom., Duckworth CA; Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Pritchard DM; Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Lin ZX; School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, People's Republic of China., Fretwell VL; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Tweedle EM; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Costello E; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Goldring CE; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Copple IM; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Park BK; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Palmer DH; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.; Clatterbridge Cancer Centre, Liverpool, United Kingdom., Kitteringham NR; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
المصدر: Oncotarget [Oncotarget] 2019 Jan 18; Vol. 10 (6), pp. 685. Date of Electronic Publication: 2019 Jan 18 (Print Publication: 2019).
نوع المنشور: Journal Article; Published Erratum
اللغة: English
بيانات الدورية: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: eCollection Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Albany, N.Y. : Impact Journals
مستخلص: [This corrects the article DOI: 10.18632/oncotarget.25497.].
التعليقات: Erratum for: Oncotarget. 2018 Jun 5;9(43):27104-27116. (PMID: 29930754)
معلومات مُعتمدة: 15957 United Kingdom CRUK_ Cancer Research UK
تواريخ الأحداث: Date Created: 20190219 Latest Revision: 20240210
رمز التحديث: 20240210
مُعرف محوري في PubMed: PMC6363008
DOI: 10.18632/oncotarget.26625
PMID: 30774766
قاعدة البيانات: MEDLINE
الوصف
تدمد:1949-2553
DOI:10.18632/oncotarget.26625